Myricetin induces cell death of human colon cancer cells via BAX/BCL2-dependent pathway

Myricetin is a flavonol found in various berries, herbs, and walnuts. Previous studies have demonstrated that myricetin has anticancer effects against several types of cancer, including hepatocarcinoma, skin carcinoma, and pancreatic cancer. However, the anticancer activity of myricetin on human col...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2014-02, Vol.34 (2), p.701-706
Main Authors: Kim, Mi Eun, Ha, Tae Kwun, Yoon, Ju Hwa, Lee, Jun Sik
Format: Article
Language:English
Subjects:
Apoptosis Inducing Factor - metabolism
bcl-2 Homologous Antagonist-Killer Protein - biosynthesis
bcl-2-Associated X Protein - metabolism
Cell Line, Tumor
Colonic Neoplasms - drug therapy
Colonic Neoplasms - genetics
Colonic Neoplasms - metabolism
Colonic Neoplasms - pathology
DNA, Neoplasm - metabolism
Flavonoids - pharmacology
Humans
Proto-Oncogene Proteins c-bcl-2 - metabolism
Signal Transduction
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myricetin is a flavonol found in various berries, herbs, and walnuts. Previous studies have demonstrated that myricetin has anticancer effects against several types of cancer, including hepatocarcinoma, skin carcinoma, and pancreatic cancer. However, the anticancer activity of myricetin on human colon cancer has not been yet established. In the present study, we investigated the anticancer effects of myricetin on HCT-15 human colon cancer cells. We found that myricetin induces cytotoxicity and DNA condensation in human colon cancer cells in a dose-dependent manner. We also determined that myricetin increases the BCL2-associated X protein/B-cell lymphoma 2 ratio, but not cleavage of caspase-3 and -9. In addition, myricetin induced the release of apoptosis-inducing factor from mitochondria. These results suggest that myricetin induces apoptosis of HCT-15 human colon cancer cells and may prove useful in the development of therapeutic agents for human colon cancer.
ISSN:1791-7530